The CooperCOO +0.52%89 Net Current Asset Value is $-9.97 as of Apr. 2026. GuruFocus rates COO with a GF Score™ of 89/100 and a GF Value™ of $100.88 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 565 Medical Devices & Instruments companies, The Cooper ranks worse than 176990.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The Cooper's net current asset value per share for the quarter that ended in Apr. 2026 was $-9.97.
The historical rank and industry rank for The Cooper's Net Current Asset Value or its related term are showing as below:
COO's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
The Cooper (NAS:COO) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
The Cooper Net Current Asset Value Related Terms
The Cooper Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for The Cooper's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs SOLV, ALGN, BAX: Net Current Asset Value Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where The Cooper's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $-9.97 mean?
The Cooper (COO) has a Net Current Asset Value of $-9.97 as of Apr. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on The Cooper and its competitors. According to the industry distribution chart, The Cooper ranks #999999 out of 565 companies in the Medical Devices & Instruments industry.
Is The Cooper's Net Current Asset Value too high?
The Cooper's current Net Current Asset Value is $-9.97. Based on the distribution chart, The Cooper ranks #999999 out of 565 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, The Cooper has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Net Current Asset Value compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #999999 out of 565 companies for Net Current Asset Value. This places The Cooper in the lower half of its industry. The industry median Net Current Asset Value is 5.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.00, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Net Current Asset Value is $-9.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Modestly Undervalued. The stock's GF Value™ is $100.88, compared to a current price of $71.39 — trading 29.2% below its estimated fair value. The current Net Current Asset Value is $-9.97. The Cooper's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For The Cooper (COO), the current Net Current Asset Value is $-9.97 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $71.39 is trading 29.2% below its estimated GF Value™ of $100.88.
GuruFocus considers The Cooper to be Modestly Undervalued.
Key valuation signals for COO:
Net Current Asset Value: $-9.97
GF Value™: $100.88 vs. price of $71.39 (29.2% below fair value)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
89GF Score
Get the complete analysis for COO
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
